Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Forteo B Pen Community Experience in Osteoporosis
NCT00577863Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2008
- Primary completion
- May 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of teriparatide in osteoporosis, sponsored by Eli Lilly and Company. Primary endpoint: Summary of Forteo B Pen Complaints at 46 weeks. Started Jan 2008; status: completed.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00577863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577863.